Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

NCT04600362 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Nummular Eczema

Interventions

DRUG: Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Sponsor

Technical University of Munich

Collaborators

[object Object]